Head of Clinical Trials Department of the FDA Madam Yvonne Adu Boahene has indicated that the new herbal medicine known as Cryptolepis sanguinolenta locally as Nibima will last two months in its clinical trial.
She said, “the trial duration is for just two months, but medication is taken for seven days of treatment.”
Speaking on one of the Media houses, Madam Yvonne Adu Boahene asserted that, the trial will be done at two sites in the Ashanti Region at the Komfo Anokye Teaching Hospital and Kumasi South Hospital.
“The FDA is happy about this and is excited, and I think it is a good step for the FDA and Ghana as a whole,” she said.
The FDA has approved a herbal medicine known as Cryptolepis sanguinolenta locally known as Nibima for clinical trials for the treatment of COVID-19.
“In the search for a treatment for the ongoing COVID-19 pandemic, researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology, (KNUST), submitted a clinical trial application in September 2020 to assess the safety and efficacy of Cryptolepis sanguinolenta as a potential treatment for COVID-19. This follows results from laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits.”